IBD2 Antibody

What is IBD2 and what are its various research contexts?

IBD2 refers to different entities depending on the research context:

• In yeast biology: IBD2 is a protein found in Saccharomyces cerevisiae (baker's yeast) with the UniProt number P53892 .

• In human biology: IBD2 often appears as a synonym for SEL1L (Suppressor of lin-12-like protein 1), a protein involved in endoplasmic reticulum quality control (ERQC) and ER-associated degradation (ERAD) .

• In inflammatory bowel disease research: The term can refer to markers used for studying inflammatory bowel disease pathogenesis and diagnosis .

Methodologically, researchers must carefully identify which IBD2 they're working with by checking:

• The species reactivity (human vs. yeast)

• The immunogen used to generate the antibody

• The specific applications validated (WB, ELISA, IHC, etc.)

• The molecular weight of the target protein

How does IBD2/SEL1L function in the ERAD pathway and why is it important for research?

SEL1L (sometimes referred to as IBD2) plays a critical role in the endoplasmic reticulum quality control (ERQC) system:

• Function: It forms part of the highly conserved SEL1L-HRD1 complex, which consists of the E3 ubiquitin ligase HRD1 and SEL1L as its adaptor protein .

• Biological importance: SEL1L enhances SYVN1 stability, plays a role in LPL maturation and secretion, and is required for normal differentiation of pancreatic epithelium .

• Research significance: The SEL1L-HRD1 complex is the most well-characterized ERAD machinery in mammals, involved in ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins .

• Phenotypic effects: SEL1L deficiency in mouse models is embryonically lethal, and conditional knockout in specific neurons (e.g., AVP neurons) results in phenotypes resembling central diabetes insipidus .

Research methodologies employing SEL1L antibodies are valuable for investigating protein quality control, cellular stress responses, and various pathological conditions related to ER dysfunction.

What's the difference between IBD2 antibodies and antibodies used as biomarkers for inflammatory bowel disease?

These represent two distinct antibody categories that shouldn't be confused:

In inflammatory bowel disease research, several antibody biomarkers are studied, including:

• Autoantibodies: pANCA (perinuclear anti-neutrophil cytoplasmic antibody), PAB (pancreatic antibody)

• Microbial antibodies: ASCA (anti-Saccharomyces cerevisiae antibody), ACCA, ALCA, AMCA, anti-OmpC, anti-Cbir1, anti-I2

For diagnostic use, these biomarkers are often combined as panels to achieve better sensitivity and specificity, as no single marker has satisfactory diagnostic accuracy .

What are the optimal protocols for using IBD2/SEL1L antibodies in Western blotting and immunoprecipitation?

Western Blot Protocol:

• Sample Preparation:

  • Lyse cells or tissues in RIPA buffer or similar

  • Load 5-30 μg of total protein per lane

• SDS-PAGE:

  • Use 12% gels for optimal separation

  • Include molecular weight markers

• Transfer:

  • Transfer to PVDF membranes (e.g., MERCK, cat. no. IPVH00010)

• Blocking:

  • Block with 5% BSA in TBST at 25°C for 60 min

• Primary Antibody:

  • Dilute IBD2/SEL1L antibody 1:500 to 1:1000

  • Incubate at 25°C for 2 hours or overnight at 4°C

• Secondary Antibody:

  • Use HRP-conjugated secondary antibody appropriate for the host species

  • Incubate at room temperature for 1 hour

• Detection:

  • Develop with enhanced chemiluminescence reagent (e.g., MERCK, cat. no. GERPN2106)

  • The expected molecular weight for human SEL1L is ~81 kDa

Immunoprecipitation Protocol:

• Incubate 600 μg of cell lysate with antibody-conjugated agarose beads (bead volume: 20 μl) for 16 hours at 4°C

• Wash beads briefly in RIPA buffer by centrifugation at 1,000 × g for 30 sec at 4°C

• Analyze by Western blotting

For proteomics applications, scale up using 500 μl of antibody-conjugated beads with approximately 10 mg of cell lysate .

How should researchers validate the specificity of IBD2/SEL1L antibodies?

Thorough validation is crucial for ensuring antibody specificity:

• Peptide Competition Assay:

  • Pre-incubate the primary antibody (e.g., 5 μg in 10 ml of 5% skim milk in TBS) with epitope-peptide-conjugated BSA (2 μg) at 25°C for 90 min

  • Use this pre-absorbed antibody as the primary antibody in Western blot

  • Loss of signal confirms specificity

• Positive and Negative Controls:

  • Test in cell lines known to express or lack the target protein

  • For SEL1L antibodies, U-251MG and U-87MG are reported positive samples

  • Include pre-immune serum as a negative control

• Knockout/Knockdown Validation:

  • Compare antibody reactivity in wild-type versus knockout or knockdown samples

  • Complete loss of signal in knockout samples confirms specificity

• Cross-Species Reactivity:

  • Test antibody performance across multiple species based on manufacturer specifications

  • Confirm that reactivity matches expected evolutionary conservation

• Molecular Weight Verification:

  • Confirm that the detected band appears at the expected molecular weight

  • For SEL1L, verify detection at approximately 81 kDa

What are the considerations for using IBD2/SEL1L antibodies in immunohistochemistry and immunofluorescence?

Immunohistochemistry Considerations:

• Tissue Preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissue sections

  • For SEL1L antibodies in IHC-P, use 1:25-1:100 dilution

• Antigen Retrieval:

  • Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Optimize retrieval time based on tissue type

• Blocking:

  • Block endogenous peroxidase with 3% hydrogen peroxide

  • Use appropriate serum blocking to reduce non-specific binding

• Controls:

  • Include positive control tissues (e.g., human gastric cancer tissue has been used for SEL1L antibody validation)

  • Use isotype controls to assess background

Immunofluorescence Considerations:

• Cell Preparation:

  • Plate cells on glass coverslips and allow 48 hours of growth

  • Fix and permeabilize cells with BD Cytofix/Cytoperm solution

  • Wash with BD Cytoperm/wash solution

• Antibody Dilution:

  • Start with manufacturer's recommended dilution and optimize as needed

  • For SEL1L, test dilutions between 1:100-1:500

• Counterstaining:

  • Use DAPI or Hoechst for nuclear counterstaining

  • Consider co-staining with ER markers to confirm SEL1L localization

• Imaging Parameters:

  • SEL1L typically shows cytoplasmic and ER localization patterns

  • Use confocal microscopy for optimal resolution of subcellular localization

How are IBD2/SEL1L antibodies used to study the relationship between ERAD dysfunction and disease pathogenesis?

IBD2/SEL1L antibodies are instrumental in investigating the connection between ER stress, ERAD dysfunction, and various diseases:

• Pancreatic Disease Research:

  • SEL1L is required for normal differentiation of pancreatic epithelium and for exocrine function

  • Antibodies enable visualization of SEL1L expression patterns in pancreatic tissue

  • Studies have shown that SEL1L deficiency in AVP neurons can lead to phenotypes resembling central diabetes insipidus

• Neurodegenerative Disease Models:

  • ERAD dysfunction contributes to protein aggregation in neurodegenerative diseases

  • SEL1L antibodies help monitor changes in ERAD components in disease models

  • Immunohistochemistry with SEL1L antibodies reveals altered expression patterns in affected tissues

• Inflammatory Bowel Disease Connection:

  • ER stress is implicated in IBD pathogenesis

  • SEL1L antibodies allow researchers to evaluate ERAD pathway integrity in intestinal samples

  • Studies can correlate SEL1L expression with disease severity or treatment response

• Cancer Research:

  • SEL1L may play a role in tumor progression

  • Antibodies enable assessment of SEL1L expression in tumor versus normal tissue

  • Immunohistochemistry of paraffin-embedded human gastric cancer tissue has been performed using SEL1L antibodies

Research approaches typically involve:

• Comparative expression analysis between healthy and diseased tissues

• Co-immunoprecipitation to identify SEL1L-interacting partners

• Pulse-chase experiments to assess protein degradation rates

• Correlation of SEL1L levels with markers of ER stress (e.g., BiP, CHOP)

How do antibody responses to SARS-CoV-2 differ in patients with inflammatory bowel disease receiving biologic therapies?

This represents an important intersection of IBD research and infectious disease immunology:

Key Findings from Clinical Studies:

• Antibody Responses After Natural Infection:

  • IBD patients on biologics show lower and less durable SARS-CoV-2 S-RBD IgG responses compared to non-IBD controls

  • By 6 months post-infection, most IBD patients lacked neutralizing antibodies

  • The magnitude of antibody decline was higher in IBD patients (3.7× decline) versus controls

  • Neutralizing capacity decreased markedly over time (10.6× decline over 6 months)

• Vaccine-Induced Antibody Responses:

  • Vaccination elicited 15-fold higher S-RBD antibody responses compared to natural infection in IBD patients

  • All vaccinated IBD patients developed neutralizing antibodies, including those on infliximab monotherapy or combination therapy

  • Spike protein receptor binding domain IgG responses were significantly higher following vaccination versus natural infection

• Response to Viral Variants:

  • In naturally infected IBD patients, antibody levels against mutant spike proteins were 3.7× lower than against wild-type spike

  • Vaccinated IBD patients showed similar antibody levels against both wild-type and mutant spike proteins

  • S-RBD IgG responses to mutant spike protein were 34.3× lower in natural infection compared to vaccine-induced antibodies

Methodological Approaches:

• Regular serum sampling at defined intervals (2-3 months)

• Fluorescent bead-based immunoassays for antibody detection

• Neutralization assays incorporating SARS-CoV-2 spike protein onto lentiviruses

• Measurement of pseudoviral entry into ACE2-expressing HEK-293 cells

These findings highlight the importance of vaccination in IBD patients receiving biologic therapies, as their antibody response to natural infection appears impaired and less durable.

What role do polymer-based antibody mimetics (iBodies) play in targeting human PD-L1, and how do they compare to conventional antibodies?

Recent advances in antibody technology have led to the development of polymer-based antibody mimetics called "iBodies":

Structure and Design:

• iBodies consist of an N-(2-hydroxypropyl)methacrylamide (pHPMA) copolymer backbone decorated with:

  • Target-specific low-molecular-weight ligands

  • Fluorescent molecules for imaging

  • Biotin for isolation applications

Specific Example - α-hPD-L1 iBodies:

• These target human PD-L1 by attaching the macrocyclic peptide WL12 to pHPMA

• Multiple WL12 ligands (5.4-8.28 per polymer) are attached to each polymer molecule

Performance Comparison with Conventional Antibodies:

Mechanism of Action:

• Multiple ligand molecules on each polymer create a strong avidity effect

• Local steric hindrance formed around the iBody-PD-L1 interface enhances ability to disrupt PD-1/PD-L1 interaction

• Improved solubility of ligands due to pHPMA hydrophilicity

Research Applications:

• Experimental tools for targeting hPD-L1

• Platform to potentiate therapeutic effects of PD-L1-targeting small molecules

• Model systems for studying immune checkpoint blockade

What are common issues when working with antibodies in IBD research and how can they be overcome?

Researchers face several challenges when using antibodies in IBD studies:

1. Low Specificity of IBD Serological Markers:

• Issue: No single antibody marker has satisfactory diagnostic accuracy for IBD

• Solution: Use antibody panels combining multiple markers (e.g., ASCA, pANCA, anti-OmpC, anti-CBir1)

• Implementation: For research studies, calculate sensitivity, specificity, and area under ROC curves for marker combinations rather than individual markers

2. Variability in Antibody Response:

• Issue: Antibody responses to specific antigens are not uniform among IBD patients

• Evidence: In one study, 85% of CD patients responded to at least one antigen but only 4% responded to all four tested antigens

• Solution: Incorporate multiple biomarkers and use standardized cutoff values across laboratories

3. Ethnic and Geographic Variations:

• Issue: Expression of antibody markers may be affected by race and geography

• Example: PAB expression showed higher positive rates (46%) among Chinese patients with CD compared to Western patients (22%)

• Solution: Include appropriate regional/ethnic controls in study designs and consider population-specific reference ranges

4. Cross-Reactivity Concerns:

• Issue: Anti-glycan antibodies (ASCA, ACCA, ALCA) may cross-react with various microbial and host antigens

• Solution: Perform absorption studies with purified antigens to confirm specificity

5. Technical Challenges:

• Issue: Different assay formats can yield variable results

• Solution: Standardize protocols across laboratories, use validated commercial kits, and include appropriate internal controls

How can researchers optimize the detection of low-abundance proteins when using IBD2/SEL1L antibodies?

For improved detection of low-abundance proteins like SEL1L:

1. Sample Enrichment Techniques:

• Immunoprecipitation: Use SEL1L antibody-conjugated agarose beads (20-500 μl) with sufficient protein lysate (600 μg to 10 mg)

• Subcellular Fractionation: Isolate ER-enriched fractions where SEL1L is predominantly located

• Sequential Extraction: Use increasingly stronger buffers to extract membrane-associated proteins

2. Signal Amplification Methods:

• Enhanced Chemiluminescence: Use high-sensitivity ECL substrates

• Tyramide Signal Amplification (TSA): Enhances sensitivity by catalytic reporter deposition

• Polymer-Based Detection Systems: Employ HRP-polymer conjugates for higher sensitivity in IHC

3. Optimized Western Blotting:

• Transfer Efficiency: Use semi-dry transfer for larger proteins or wet transfer with SDS for hydrophobic proteins

• Blocking Optimization: Test BSA (5%) versus milk (5%) as SEL1L antibodies may perform differently with different blockers

• Antibody Concentration: For SEL1L detection, consider higher concentrations (1:25-1:100) for IHC applications

• Extended Incubation: Perform primary antibody incubation overnight at 4°C

4. Advanced Microscopy for Imaging:

• Confocal Microscopy: For better resolution of SEL1L subcellular localization

• Deconvolution: Apply computational methods to improve signal-to-noise ratio

• Super-Resolution Techniques: Consider STED or STORM for detailed localization studies

5. Controls for Validation:

• Positive Controls: Include samples known to express SEL1L (e.g., U-251MG and U-87MG cell lines)

• Spike-In Controls: Add recombinant protein to samples as a reference standard

• Comparative Detection: Use multiple antibodies targeting different epitopes of the same protein

What considerations are important when analyzing antibody responses to SARS-CoV-2 in IBD patients?

When studying SARS-CoV-2 antibody responses in IBD patients, researchers should address several methodological considerations:

1. Timing of Sample Collection:

• After Natural Infection:

  • Initial sampling: 3-6 weeks post-positive PCR test

  • Follow-up sampling: 2-3 month intervals to track antibody persistence

  • In research studies, average duration between PCR+ and serum sampling was 3.9 weeks (median 2.6, range 1.0-12.6)

• After Vaccination:

  • For mRNA vaccines: 3-4 weeks after second dose

  • For adenovirus vector vaccines: 3-4 weeks after vaccination

  • In studies, mean duration was 3.3 weeks (range 1-10 weeks) for mRNA vaccines and 3.1 weeks (range 1.6-3.6 weeks) for adenovirus vector vaccines

2. Antibody Assay Selection:

• Primary Detection: IgG antibodies to spike protein receptor binding domain (S-RBD)

• Methodology: Fluorescent bead-based immunoassay using flow cytometry provides high dynamic range

• Functional Assessment: Include neutralization assays incorporating SARS-CoV-2 spike protein onto lentiviruses to measure pseudoviral entry into ACE2-expressing cells

3. Controlling for Treatment Variables:

• Biologic Therapy Classification:

  • Categorize patients by specific biologic (e.g., infliximab vs. vedolizumab)

  • Record monotherapy vs. combination therapy with immunomodulators

  • Document duration of treatment and drug levels where possible

• Statistical Analysis:

  • Use multivariate analysis to adjust for confounding factors

  • Consider propensity score matching to minimize treatment selection bias

  • Perform stratified analysis based on medication type and dosage

4. Variant Testing:

• Include testing against both wild-type and variant spike proteins

• Compare neutralization capacity against wild-type and variants (e.g., N501Y mutation)

• Calculate fold-change in antibody levels between wild-type and variant responses

5. Demographic and Clinical Correlations:

• Match IBD patients with appropriate controls by age, sex, and comorbidities

• Record IBD phenotype, disease activity, and extra-intestinal manifestations

• Consider the impact of steroid use, as it has been associated with more severe COVID-19 in IBD patients

How are antibody markers being used to develop personalized treatment approaches for inflammatory bowel disease?

Antibody profiling is emerging as an important tool for treatment personalization in IBD:

Current Applications in Treatment Selection:

• Predicting Response to Biologics:

  • Studies have shown that infliximab has reduced efficacy in pANCA-positive CD patients

  • pANCA-positive/ASCA-negative CD patients show poorer response to infliximab

  • Similar findings reported in pANCA-positive/ASCA-negative UC patients

• Guiding Antibiotic Therapy:

  • CD patients positive for anti-I2 or anti-OmpC (antibodies against intestinal bacteria) showed better response to antibiotic treatment

  • This allows for targeted use of antibiotics in the subset of patients most likely to benefit

• Treatment Resistance Prediction:

  • pANCA-positive UC has been reported to be more resistant to medical treatments in general

  • This information can help clinicians prepare alternative treatment strategies earlier

Research Methodologies for Developing Personalized Approaches:

• Antibody Signature Analysis:

  • Comprehensive profiling of multiple antibodies (ASCA, pANCA, ACCA, ALCA, anti-OmpC, anti-Cbir1)

  • Correlation of antibody patterns with treatment outcomes in retrospective and prospective cohorts

  • Development of predictive algorithms incorporating antibody signatures

• Integration with Other Biomarkers:

  • Combining antibody data with genetic markers (e.g., NOD2/CARD15 variants)

  • Incorporating microbiome profiles alongside antibody measurements

  • Multi-omics approaches to generate comprehensive patient profiles

• Longitudinal Monitoring:

  • Tracking changes in antibody profiles over time

  • Assessing how antibody dynamics correlate with disease flares or remission

  • Evaluating antibody levels before and after therapeutic interventions

Future Directions:

• Development of point-of-care antibody panels for rapid clinical decision-making

• Creation of risk stratification tools that include antibody profiles

• Integration of antibody data into clinical trial designs for better patient selection

• Exploration of novel antibody targets that may provide additional predictive value

What are the most promising future applications of antibody-based technologies in inflammatory bowel disease research?

Several innovative approaches are emerging in antibody-based IBD research:

1. Novel Antibody Biomarker Discovery:

• Screening for novel autoantibodies using high-throughput technologies

• Example: A BRD2 autoantibody was identified as a diagnostic marker in HCC using a cyclic peptide library screening approach

• This methodology could be adapted to discover new IBD-specific autoantibodies

• Potential approach: Screen B-cell hybridomas from IBD patients against intestinal cell lines

2. Therapeutic Antibody Mimetics:

• Development of polymer-based antibody mimetics (iBodies) targeting IBD-relevant molecules

• Similar to the α-hPD-L1 iBodies that showed comparable efficacy to therapeutic antibodies

• Advantages include chemical synthesis, high stability, and strong avidity effects

• Potential to develop cheaper and more stable alternatives to current biologics

3. Advanced Imaging Applications:

• Antibody-based imaging to visualize inflammation in real-time

• Fluorescently labeled antibodies against IBD-relevant targets

• Integration with endoscopic technologies for enhanced visualization during procedures

• Example: Similar to how radiolabeled WL12 was developed for imaging PD-L1 expression in cancer

4. Precision Monitoring of Treatment Response:

• Development of antibody-based assays to monitor drug levels and anti-drug antibodies

• Multiplex platforms measuring both therapeutic antibody concentrations and patient-derived antibodies

• Real-time monitoring systems that allow for treatment optimization

5. Antibody Engineering for Gut-Specific Targeting:

• Design of antibody fragments with enhanced intestinal tissue penetration

• Development of bispecific antibodies targeting multiple IBD pathways simultaneously

• Orally administered antibody formulations for localized intestinal delivery

6. Predictive Medicine Applications:

• Machine learning algorithms incorporating antibody profiles with other biomarkers

• Development of comprehensive risk prediction tools for disease progression

• Early intervention strategies based on antibody-defined patient subgroups

How do the characteristics of autoantibodies in IBD differ from those in other autoimmune conditions, and what are the research implications?

Understanding the unique characteristics of IBD-associated autoantibodies has important research implications:

Distinctive Features of IBD Autoantibodies:

• Limited Pathogenic Potential:

  • Unlike autoantibodies in diseases like vasculitis, IBD-associated pANCA does not activate neutrophil respiratory burst

  • IBD autoantibodies appear to be markers of aberrant immune responses rather than direct pathogenic effectors

• Cross-Reactivity with Microbial Antigens:

  • pANCA in IBD is thought to be induced by cross-reaction with intestinal bacterial antigens

  • This suggests a mechanistic link between microbiome dysbiosis and autoimmunity in IBD

• Variable Expression Patterns:

  • Considerable heterogeneity in antibody expression between patients

  • Example: In CD patients, ASCA was detected in 56%, OmpC in 55%, I2 in 50%, and ANCA in 23%

• Phenotype Association:

  • pANCA-positive CD exhibits a clinical phenotype resembling UC

  • PAB-positive CD cases show higher frequencies of penetration, anal lesions, and extra-intestinal complications

Research Implications:

• Patient Stratification Approaches:

  • Define IBD subgroups based on autoantibody profiles

  • Design clinical trials with stratification by antibody status

  • Develop personalized treatment algorithms incorporating antibody data

• Mechanistic Investigations:

  • Explore the relationship between intestinal microbiota composition and autoantibody development

  • Investigate how genetic factors influence autoantibody production in IBD

  • Examine the impact of diet and environmental factors on antibody responses

• Methodological Considerations:

  • Develop standardized assays with established cut-off values

  • Include appropriate controls to account for ethnic and geographic variations

  • Consider longitudinal sampling to assess antibody dynamics during disease course

• Translational Opportunities:

  • Use autoantibody profiles to guide microbiome-targeted interventions

  • Explore tolerization approaches to dominant autoantibody targets

  • Develop companion diagnostics for existing and emerging therapies

• Unique Research Challenges:

  • Need for larger cohorts due to heterogeneous antibody expression

  • Requirement for robust assay validation given the impact of environmental factors

  • Importance of functional studies to determine whether antibodies contribute to pathogenesis